## 

||||||Page|
|---|---|---|---|---|---|
|ForewordbytheChairandChiefExecutive|||||3|
|Ouraim||||||
||||||5|
|Trustees’report||||||
|Aboutus|||||5|
|Ourimpactin2022-Goalsandachievements|||||6|
|Lookingaheadto2023—Our|aimsandgoals||||34|
|Ourfinances|||||35|
|OurStructure,Governanceandmanagement|||||38|
|Trustees’responsibilitiesstatement|||||42|
|Referenceandadministrativedetailsofthecharity,||itstrustees||andadvisers|44|
|Independentauditorsreport|||||46|
|Statement<br>offinancial<br>activities,|incorporating|income|and|<br>expenditure|51|
|account||||||
|Balancesheet|||||52|
|Cashflowstatement|||||54|
|Notestothefinancialstatements|||||55|





## 



## 

## 



## 








## 



## 



## 




## 

## 



## 

## 




## 




## **THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK (A company limited by guarantee)** 


_(Pictured: The zipline at our annual young adult residential weekend at Mount Cook proved to be incredibly popular_ 

## **Reaching and engaging with our patient community - Marketing and Communications** 

In line with our charitable objectives to reach and engage more kidney patients and to reduce inequalities among the most vulnerable groups, the Marketing and Communications Team plays a vital role in ensuring the patient community are aware of the Charity and more importantly the support we provide. The Team continues to work collaboratively with and support colleagues right across the Charity. Reflecting on 2022, the team’s impact has been unprecedented in terms of what Kidney Care UK has been able to deliver and achieve, especially when measured against our charitable objectives and key department plans. 

Our response to the pandemic has been recognised as an exemplar case study while our response to the cost-of-living crisis has received national media coverage and recognition from the sector with the team being finalists in the Charity Film and Team of the Year categories at the Third Sector Awards. 

To ensure that the Charity maintained and advanced its position as the leading kidney patient support charity and a charity worth giving to, we focused on five core strategic themes driven by our department plans: 

- To deliver a best-in-class marketing, communications and digital function 

- To maximise our reach and engagement with kidney patients at a national and regional level 

- To gather insight and represent the voice of the patient to drive change and promote our key campaign theme 

- Continue to develop a leading suite of patient support information materials 

- To create patient information content beyond medicine, supporting the delivery and promotion of our products and services. 

## **Making our information easier to access through our website and digital work** 

_**“Not being able to do anything to help my brother when he was going through a terrible time was so difficult. I went online and I came across your charity website. It was all there and felt like a comfort blanket to me. To the people who are going through it, not just patients but their wider circle of family and friends too, a resource like your website really is a lifeline.”**_ 

15 



## 









## 

## 





## 

## 





## 



## 

## 



## 



## 

## 



## 




## 

## 





## 






## 



## 

## 



## 

## 

## 



## 

## 

## 



## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 



## 

## 



**THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK** 

## **(A company limited by guarantee)** 

## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK** 

## **Opinion** 

We have audited the financial statements of The British Kidney Patient Association t/a Kidney Care UK (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). 

In our opinion the financial statements: 

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006. 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report. 

46 



**THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK** 

## **(A company limited by guarantee)** 

## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK (CONTINUED)** 

## **Other information** 

The Trustees are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditors' report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## **Matters on which we are required to report by exception** 

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion: 

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or 

- sufficient and proper accounting records have not been kept; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of trustees** 

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. 

47 



**THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK** 

## **(A company limited by guarantee)** 

## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK (CONTINUED)** 

## **Auditors' responsibilities for the audit of the financial statements** 

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Act and relevant regulations made or having effect thereunder. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: 

_Capability of the audit in detecting irregularities, including fraud_ The objectives of our audit are to identify and assess the risks of material misstatement of the financial statements due to fraud or error; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud or error; and to respond appropriately to those risks. 

Based on our understanding of the charity and industry, and through discussion with the directors and other management (as required by auditing standards), we identified that the principal risks of non-compliance with laws and regulations related to health and safety, anti-bribery and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to: posting inappropriate journal entries to increase income or reduce expenditure, management bias in accounting estimates and judgemental areas of the financial statements such as accounting treatment of grants awarded not yet claimed and accounting for legacies receivable. Audit procedures performed by the engagement team included: 

- Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud; and 

- Assessment of identified fraud risk factors; and 

- Challenging assumptions and judgments made by management in its significant accounting estimates; and 

- Performing analytical procedures to identify and unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and 

- Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business; and 

- Reading minutes of meetings of those charged with governance; and 

- Review of significant and unusual transactions and evaluation of the underlying financial rational supporting the transactions; and 

- Identifying and testing journal entries, in particular any manual entries made at the year end for financial statement preparation; and 

- Performing substantive procedures on grant approvals at board level, progress of conditions being met and identification of grants not recognised that may indicate risks of  material misstatement due to fraud; and 

- • Confirmation of legacy estimations susceptible to fraud or irregularity from solicitors. 

48 



**THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK** 

## **(A company limited by guarantee)** 

## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK (CONTINUED)** 

There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it.  Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. 

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also: 

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. 

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the charitable company's internal control. 

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees. 

- Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the charitable company to cease to continue as a going concern. 

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. 

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. 

49 



**THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK** 

## **(A company limited by guarantee)** 

## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK (CONTINUED)** 

## **Use of our report** 

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed. 


Kreston Reeves LLP Chartered Accountants Statutory Auditor Chichester 

## **Date** 20 July 2023 

Kreston Reeves LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006. 

50 



## 

|||Endowment||Restricted||Unrestricted|Total|Total|
|---|---|---|---|---|---|---|---|---|
|||Funds||Funds||Funds|Funds|Funds|
|||2022||2022||2022|2022|2021|
|||£||£||£|£|£|
|Incomeandendowments|||||||||
|from:|||||||||
|||||||2,019,194|2,234,674|1,272,987|
|Donationsandlegacies|4||-|215,480|||||
|Othertradingactivities|5||-||=|58,682|58,682|62,218|
|Investments|6|1,911|||-|693,543|695,454|679,056|
|Totalincomeand|||||||||
|endowments||<br>1,911|<br>|<br>215,480|<br>|<br>2,771,419|<br>2,988,810|<br>2,014,261|
|Expenditureon:|||||||||
|Raisingfunds|7||-||-|850,847|850,847|759,203|
|Charitableactivities|<br>8|<br>1,911|<br>|<br>51,714|<br>|<br>3,522,174|<br>3,575,799|<br>3,296,179|
|Totalexpenditure|<br>|<br> <br>1,911|<br> <br>|<br> <br>51,714|<br> <br>|<br> <br>4,373,021|<br> <br>4,426,646|<br> <br>4,055,382|
|Netincome/|||||||||
|(expenditure)beforenet|||||||||
|gainsoninvestment|||-|163,766||(1,601,602)|(1,437,836)|(2,041,121)|
|Net(losses)/gainson<br>investments|12|(6,671)|||a|(2,791,421)|(2,798,092)|2,869,412|
|Netmovementinfunds||<br> <br>(6,671)|<br> <br>|<br> <br>163,766|<br> <br>|<br> <br>(4,393,023)|<br> <br>(4,235,928)|<br> <br>828,291|
|Reconciliationoffunds:|||||||||
|Totalfundsbroughtforward<br>Netmovementinfunds||91,848<br>(6,671)|<br>|34,882<br>163,766|<br>|32,802,743<br>(4,393,023)|32,929,473<br>(4,235,928)|32,101,182<br>828,291|
|Totalfundscarried<br>forward||<br>85,177<br>|<br> <br>|<br>198,648<br>|<br> <br>|<br>28,409,720<br>|<br>28,693,545<br>|<br>32,929,473<br>|





## 

## 

||Note|£|2022<br>£||2021|
|---|---|---|---|---|---|
|FIXEDASSETS||||||
|Tangibleassets<br>Investments|17<br>18||387,650<br>28,042,921||394,486<br>32,875,893|
||||28,430,571||33,270,379|
|CURRENTASSETS||||||
|Debtors<br>Cashatbankandinhand|19|915,284<br>272,179||503,110<br>511,802||
|||1,187,463||1,014,912||
|CREDITORS:amountsfallingduewithinone<br>year|20|(758,827)||(1,208,316)||
|NETCURRENTASSETS/(LIABILITIES)|||428,636||(193,404)|
|TOTALASSETSLESSCURRENTLIABILITIES|||28,859,207||33,076,975|
|CREDITORS:amountsfallingdueaftermore<br>thanoneyear|21||(165,662)||(147,502)|
|TOTALNETASSETS|||28,693,545||32,929,473|





# 22 June 2023 



54 



## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 

||Total|Total|
|---|---|---|
||Funds|Funds|
||2022|2021|
||£|£|
|Donations|1,116,898|573,912|
|Legacies|1,117,776|688,731|
|Grants|-|10,344|
||<br>2,234,674<br>|<br>1,272,987<br>|



## 

|Total|Total|
|---|---|
|Funds|Funds|
|2022|2021|
|£|£|
|58,682|62,218|





## 

## 

|||Total|Total|
|---|---|---|---|
|||Funds|Funds|
|||2022|2021|
|||£|£|
|Incomefromlisted|investments|695,416|679,032|
|InvestmentIncome|<br>-Cash|38|24|
|||<br> <br>695,454|<br> <br>679,056|



## 

||Total|Total|
|---|---|---|
||Funds|Funds|
||2022|2021|
||£|£|
|Costofraisingvoluntaryincome|693,227|584,142|
|Investmentmanagementfees|157,620|175,061|
||<br>850,847<br>|<br>759,203<br>|





## 

## 

## 

||||Activities|Grant|||
|---|---|---|---|---|---|---|
||||undertaken|fundingof|Support||
||||directly|activities|Costs|Total2022|
|||Note|£|£|£|£|
||DirectPatientSupport|9,10,11|<br>1,374,342|<br>1,296,022|<br>905,435|<br>3,575,799|
||||Activities||||
||||undertaken|Grantfunding|Support||
||||directly|ofactivities|Costs|Total2021|
||||£|£|£|£|
||DirectPatientSupport|9,10,11|<br>1,259,916|<br>1,358,012|<br>678,251|<br>3,296,179|
||Analysisofdirectcosts||||||
||||||2022|2021|
||||Note||£|£|
||Staffcosts||||931,288|771,384|
||Counselling||||16,173|4,512|
||Advocacy<br>Policyservice||||28,438<br>66,437|24,235<br>69,619|
||PatientInformation||||332,006|390,166|
||||8|<br>|<br> <br>1,374,342|<br> <br>1,259,916|
|10.|Analysisofgrantfunding|activities|||||
|||||Grantsto|Grantsto|Total|
|||||Institutions|Individuals||
|||||2022|2022|2022|
||||Note|£|£|£|
||Grants,patientsupport||8|<br>547,856|<br>748,166|<br>1,296,022|
|||||Grantsto|Grantsto|Total|
|||||Institutions|Individuals||
|||||2021|2021|2021|
|||||£|£|£|
||Grants,patientsupport||8|808,463|549,549|1,358,012|





## 

## 

## 

|Note|2022<br>£|2021<br>£|
|---|---|---|
|Grantsbytype<br>Postfunding,projectsandequipment<br>Smallgrants<br>DialysisFreedom<br>MountCook<br>Grantstopatients<br>Research/Development|405,866<br>18,970<br>40,145<br>26,525<br>748,166<br>56,350|576,708<br>36,997<br>35,627<br>1,487<br>549,549<br>157,644|
||<br> <br>1,296,022|<br> <br>1,358,012|
||2022<br>£|2021<br>E|
|GrantsbyInstitution<br>AltnagelvinHospital<br>BartsHealthNHSTrust<br>BritishRenalSociety<br>Childrenshospitals<br>DialysisFreedom<br>EvelinaChildren'sHospital<br>GreatOrmondStreetHospitalforChildren<br>HullRoyalInfirmary<br>King'sCollegeHospital<br>UniversityofManchester<br>MountCook<br>NewcastleFreemanHospital<br>NorthernGeneral-Sheffield<br>Othergrants<br>PNNGPaediatricNephrologyGroup<br>QueenAlexandraHospital-WessexKidneyCentre<br>Queen'sUniversityHospitalBelfast<br>RenalSpecialInterestGroup<br>RenalPsychologicalServicesGroup<br>Smallgrants<br>SouthmeadHospital&UniversityofBristol<br>SunderlandRoyalHospital<br>SouthamptonChildren'sHospital<br>RoyalStokeUniversityHospital<br>UniversityHospitalWalesPaediatricUnit<br>WalsallManorHospital<br>YoungAdultKidneyGroup(YAKG)<br>Lapsedorcancelledgrantsforprioryears|99,868<br>53,854<br>-<br>;<br>40,145<br>10,000<br>17,200<br>z<br>26,223<br>16,089<br>26,525<br>.<br>98,154<br>52,976<br>1,777<br>50,659<br>3<br>16,000<br>-<br>18,970<br>:<br>.<br>95,741<br>40,553<br>67,542<br>:<br>2,000<br>(186,420)|‘<br>;<br>113,970<br>2,000<br>35,627<br>-<br>:<br>42,673<br>49,728<br>:<br>1,487<br>103,740<br>-<br>157,825<br>:<br>28,968<br>65,796<br>:<br>8,000<br>36,997<br>101,767<br>48,885<br>-<br>:<br>-<br>11,000<br>:<br>-|
||<br>547,856<br>|<br>808,463<br>|





## 

## 

## 

|11.|Analysisofsupportcosts|Note|2022|2021|
|---|---|---|---|---|
||||£|£|
||Governance||185,334|122,446|
||Finance||101,782|80,916|
||InformationTechnology<br>HumanResources||157,948<br>73,975|141,983<br>85,997|
||Premisesandfacilities<br>Communications||157,088<br>229,308|104,275<br>142,634|
|||8|<br> <br>905,435|<br> <br>678,251|
|12.|Netgainsoninvestments||2022|2021|
||||£|£|
||Realised(losses)/gainsoninvestments<br>Unrealised(losses)/gainsoninvestments<br>18<br>Realisedforeignexchangegainsoncashheldininvestments||(399,112)<br>(2,434,742)<br>35,762|(11,076)<br>2,880,488<br>-|
||||<br>(2,798,092)|<br>2,869,412|



## 

## 

|2022|2021|
|---|---|
|£|£|
|16,600|16,470|





## 

## 

## 

||2022|2021|
|---|---|---|
||£|£|
|Wagesandsalaries|1,704,632|1,319,226|
|Socialsecuritycosts|164,851|123,559|
|Pensioncosts|94,292|80,213|
||<br> <br>1,963,775|<br> <br>1,522,998|



||2022|2021|
|---|---|---|
||No.|No.|
|Grantsandpatientaid(includingsupportcosts)<br>Fundraising<br>AdvocacyService<br>Counsellingservice|7<br>13<br>18<br>4|6<br>8<br>16<br>3|
|Policyservice|3|2|
|Managementandadministration|<br>11|<br>10|
||56|45|



||2022|||2021||
|---|---|---|---|---|---|
||No.|||No.||
|£60-70k<br>£70-80k||1<br>1|<br>|2|<br>-|
|£80-90k|||-||-|
|£90-100K<br>£100k-110k||1|-<br>|1|<br>-|





## 

## 

## 

## 

## 

||Landand_||Fixturesand|Office||
|---|---|---|---|---|---|
||buildings||fittings|Equipment|Total|
||£||£|£|£|
|Costorvaluation||||||
|At1January2022|395,595||85,613|109,112|590,320|
|Additions||-|689|20,019|20,708|
|At31December2022|<br> <br>395,595|<br> <br>|<br> <br>86,302|<br> <br>129,131|<br> <br>611,028|
|Depreciation||||||
|At1January2022|65,537||50,379|79,918|195,834|
|Chargefortheyear|4,601||5,538|17,405|27,544|
|At31December2022|<br> <br>70,138|<br> <br>|<br> <br>55,917|<br> <br>97,323|<br> <br>223,378|
|Netbookvalue||||||
|At31December2022|<br>325,457|<br>|<br>30,385|<br>31,808|<br>387,650|
|At31December2021|330,058<br>|<br>|35,234<br>|29,194<br>|394,486<br>|





## 

## 

## 

|||2022|2021|
|---|---|---|---|
|||£|£|
|Costorvaluation||||
|At1January||31,844,444|31,174,221|
|Additions||4,543,899|4,056,782|
|Disposals||(6,960,848)|(6,267,047)|
|Net(loss)/gainonrevaluation||(2,434,742)|2,880,488|
|Marketvalueat31December||<br>26,992,753|<br>31,844,444|
|Cashbalances||1,050,168|1,031,449|
|Totalmarketvalueat31December|<br>|<br> <br>28,042,921|<br> <br>32,875,893|
|Investmentsatmarketvaluecomprise:||||
||UK|Overseas|Total|
||2022|2022|2022|
||£|£|£|
|Listedinvestments|12,389,053|14,603,700|26,992,753|
|Cashheldbyinvestmentmanagers|1,050,168|-|1,050,168|
||<br> <br>13,439,221|<br> <br>14,603,700|<br> <br>28,042,921|



||2022|2021|
|---|---|---|
||£|£|
|Fixedinterest|3,638,655|3,679,968|
|Equities|19,753,831|23,753,976|
|Property|2,628,684|1,795,406|
|Alternatives|971,583|2,615,094|
|Cashheldbyinvestmentmanagers|1,050,168|1,031,449|
|Total|<br>___28,042,921<br>|<br>32,875,893<br>|





## 

## 

|19.|Debtors|||
|---|---|---|---|
|||2022|2021|
|||£|£|
||Duewithinoneyear|||
||Otherdebtors|849,360|402,612|
||Prepaymentsandaccruedincome|65,924|100,498|
|||<br>915,284|<br>503,110|



|||2022|2021|
|---|---|---|---|
|||£|E|
||TradeCreditors|124,367|381,738|
||Accrualsanddeferredincome|50,968|71,888|
||OtherCreditors|20,323|-|
||Grantspayable|563,169|754,690|
|||<br> <br>758,827|<br> <br>1,208,316|
|21.|Creditors:Amountsfallingdueaftermorethanoneyear|||
|||2022|2021|
|||£|E|
||Grantspayable|165,662<br>|147,502<br>|





## 

## 

## 

||Balanceat||||Transfer||Balanceat31|
|---|---|---|---|---|---|---|---|
||1January|||Gains/|between||December|
||2022|Income|Expenditure|(Losses)|funds||2022|
||£|£|£|£|||£|
|UnrestrictedFunds||||||||
|DesignatedFunds|30,000,000|-|“|-|(2,000,000)||28,000,000|
|GeneralFund|2,802,743|2,771,419|(4,373,021)|(2,791,421)|2,000,000||409,720|
|TotalUnrestrictedFund<br> <br>|<br> <br>32,802,743|<br> <br>2,771,419|<br> <br>(4,373,021)|<br> <br>(2,791,421)|<br>|<br> <br>-|<br> <br>28,409,720|
|EndowmentFunds||||||||
|EndowmentFund<br>|<br>91,848|<br>1,911|<br>(1,911)|<br>(6,671)||<br>=|<br>85,177|
|RestrictedFunds||||||||
|KidneyMachine|34,882|-|-|-||-|34,882|
|ChildrenandYoungActivity<br>Breaks|7|4,221|(1,221)|-||-|-|
|TheAdvocacyOfficerFund|-|11,600|(11,600)|-||-|:|
|KidneyKitchen|-|45,034|=|*||-|45,034|
|MyRenalCare|-|15,000|-|-||-|15,000|
|PatientInformation|-|90,200|(3,000)|-||-|87,200|
|ExeterandDistrictKPA|-|20,000|(3,468)|-||-|16,532|
|Hardship,welfareand<br>benefits|-|21,200|(21,200)|-||-|-|
|Scotland|.|11,225|(11,225)|-||.|7|
|TotalRestrictedFunds<br>|<br>34,882|<br>215,480|<br>(51,714)|<br>-||<br>=|<br>198,648|
|TotalofFunds<br> <br>|<br>32,929,473<br>|<br>2,988,810<br>|<br>(4,426,646)<br>|<br>(2,798,092)<br>|<br>|<br>-<br>|<br>28,693,545<br>|





## 

## 

|Statementoffunds-prioryear||||||||
|---|---|---|---|---|---|---|---|
||Balanceat||||||Balanceat31|
||1January||||Gains/||December|
||2021||Income|Expenditure|(Losses)||2021|
||£||£|£|£||£|
|UnrestrictedFunds||||||||
|DesignatedFunds|30,000,000||-|-||-|30,000,000|
|GeneralFund|1,978,460||1,973,182|(4,005,679)|2,856,780||2,802,743|
|TotalUnrestrictedFund<br> <br>|<br> <br>31,978,460|<br> <br>|<br> <br>1,973,182|<br> <br>(4,005,679)|<br> <br>2,856,780|<br>|<br> <br>32,802,743|
|EndowmentFunds||||||||
|EndowmentFund<br>|<br>79,216|<br>|<br>1,892|<br>(1,892)|<br>12,632||<br>91,848|
|RestrictedFunds||||||||
|KidneyMachine|42,882||-|(8,000)||=|34,882|
|TheAdvocacyOfficerFund||-|34,567|(34,567)||=|<|
|KidneyKitchen|624||3,500|(4,124)||“|-|
|Other||=|1,120|(1,120)||-|-|
|TotalRestrictedFunds<br>|<br>43,506|<br>|<br>39,187|<br>(47,811)||<br>-|<br>34,882|
|TotalofFunds<br> <br>|<br>32,101,182<br>|<br> <br>|<br>2,014,261<br>|<br>(4,055,382)<br>|<br>2,869,412<br>|<br> <br>|<br>32,929,473<br>|





## 

## 

## 



## 

## 

## 

## 

||Restricted|Unrestricted||
|---|---|---|---|
||Funds|Funds|TotalFunds|
||2022|2022|2022|
||£|£|£|
|Tangiblefixedassets<br>Fixedassetinvestments<br>Currentassets<br>Creditorsduewithinoneyear<br>Creditorsdueinmorethanoneyear|-<br>85,177<br>198,648<br>-<br>-|387,650<br>927,957,744<br>988,815<br>(758,827)<br>(165,662)|387,650<br>28,042,921<br>1,187,463<br>(758,827)<br>(165,662)|
||<br> <br>283,825|<br> <br>28,409,720|<br> <br>28,693,545|
|Analysisofnetassetsbetweenfunds-priorperiod||||
||Restricted||Unrestricted||
||Funds|Funds|TotalFunds|
||2021|2021|2021|
||£|£|£|
|Tangiblefixedassets<br>Fixedassetinvestments<br>Currentassets<br>Creditorsduewithinoneyear<br>Creditorsdueinmorethanoneyear|-<br>91,848<br>34,882<br>-<br>-|394,486<br>32,784,045<br>980,030<br>(1,208,316)<br>(147,502)|394,486<br>32,875,893<br>1,014,912<br>(1,208,316)<br>(147,502)|
||<br> <br> <br>122,722|<br> <br> <br>32,802,743|<br> <br> <br>32,929,473|
|Reconciliationofnetmovementinfundstonetcashflowfromoperating||activities||
|||2022|2021|
|||£|£|
|Netincome/(expenditure)forthereportingperiod(aspertheStatementof||||
|FinancialActivities)||(4,235,928)|828,291|
|Adjustmentsfor:<br>Depreciationcharges<br>Realisedandunrealisedlosses/(gains)oninvestments<br>Exchangegainoninvestments||27,544<br>2,798,092<br>35,762|22,774<br>(2,880,488)<br>-|
|Dividends,interestandrentsfrominvestments<br>(Increase)/decreaseindebtors<br>Increase/(decrease)increditors||(695,454)<br>(412,174)<br>(431,329)|(679,056)<br>(360,061)<br>211,908|
|Netcash(usedin)operatingactivities||<br>(2,913,487)<br>|<br>(2,856,632)<br>|



## 



## 

## 

|||Note|2022|2021|
|---|---|---|---|---|
||||£|£|
||Cashinhand<br>Cashheldaspartofinvestments||272,179<br>1,050,168|511,802<br>1,031,449|
||Totalcashandcashequivalents|<br> <br>26|<br> <br>1,322,347|<br> <br>1,543,251|
|26.|Analysisofchangeindebt|At||At31|
|||1January||December|
|||2022|Cashflows|2022|
||Cashatbankandinhand|511,802|(239,623)|272,179|
||Cashheldaspartofinvestments|<br>1,031,449|<br>18,719|<br>1,050,168|
|||1,543,251<br>|(220,904)<br>|1,322,347<br>|



## 



## 

## 

## 

|At31December2022thecompanyhadannualcommi<br>follows:|tmentsundernon-cancellableoperating|leasesas||
|---|---|---|---|
||2022|2021||
||£||£|
|Other<br>Withinoneyear<br>Between2and5years<br>Over5years|<br>2,285<br>3,935<br>:|<br>2,285<br>5,891<br>330|<br> <br> <br>|
||<br>6,220|<br>8,506|<br>|
|LandandBuildings||||
|Withinoneyear|23,067|23,067||
|Between2and5years|<br>60,181|<br>83,248|<br>|
||83,248<br>|106,315<br>|<br>|



## 



## 

## 

## 

|||Endowment|||Restricted||Unrestricted||
|---|---|---|---|---|---|---|---|---|
|||Funds|||Funds||Funds|Total|
||Note|2021|||2021||2021|2021|
||||£||£||£|£|
|Incomeandendowments|||||||||
|from:|||||||||
|Donationsandlegacies||||-|39,187||1,233,800|1,272,987|
|Othertradingactivities||||-||:|62,218|62,218|
|Investments||1,892||||=|677,164|679,056|
|Totalincomeand|||||||||
|endowment||<br>1,892|<br>||<br>39,187||<br>1,973,182|<br>2,014,261|
|Expenditureon:|||||||||
|Raisingfunds||||-||-|759,203|759,203|
|Charitableactivities|8,10|1,892|||47,811||3,246,476|3,296,179|
|Totalexpenditure|<br>|<br> <br>1,892|<br> <br>|<br>|<br> <br>47,811|<br>|<br> <br>4,005,679|<br> <br>4,055,382|
|Netincome/(expenditure)|||||||||
|beforenet(losses)/gainson|||||||||
|investment||||-|(8,624)||(2,032,497)|(2,041,121)|
|Netgainsoninvestments|12|12,632||||7|2,856,780|2,869,412|
|Netmovementinfunds|<br>|<br> <br>12,632|<br> <br>|<br> <br>|<br> <br>(8,624)|<br> <br>|<br> <br>824,283|<br> <br>828,291|
|Reconciliationoffunds:|||||||||
|Totalfundsbroughtforward||79,216|||43,506||31,978,460|32,101,182|
|Netmovementinfunds||<br>12,632|<br>|<br>|<br>(8,624)|<br>|<br>824,283|<br>828,291|
|Totalfundscarriedforward|22|<br>91,848<br>|<br> <br>|<br> <br>|<br>34,882<br>|<br> <br>|<br>32,802,743<br>|<br>32,929,473<br>|